These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32682440)

  • 1. Blocking IL-1 to prevent respiratory failure in COVID-19.
    van de Veerdonk FL; Netea MG
    Crit Care; 2020 Jul; 24(1):445. PubMed ID: 32682440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.
    Dimopoulos G; de Mast Q; Markou N; Theodorakopoulou M; Komnos A; Mouktaroudi M; Netea MG; Spyridopoulos T; Verheggen RJ; Hoogerwerf J; Lachana A; van de Veerdonk FL; Giamarellos-Bourboulis EJ
    Cell Host Microbe; 2020 Jul; 28(1):117-123.e1. PubMed ID: 32411313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
    Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G
    Proc Natl Acad Sci U S A; 2020 Aug; 117(32):18951-18953. PubMed ID: 32699149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
    Day JW; Fox TA; Halsey R; Carpenter B; Kottaridis PD
    Br J Haematol; 2020 Jul; 190(2):e80-e83. PubMed ID: 32438450
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
    Franzetti M; Pozzetti U; Carugati M; Pandolfo A; Molteni C; Faccioli P; Castaldo G; Longoni E; Ormas V; Iemoli E; Piconi S
    Int J Infect Dis; 2020 Aug; 97():215-218. PubMed ID: 32422376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
    Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
    J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.
    Colafrancesco S; Scrivo R; Barbati C; Conti F; Priori R
    Front Immunol; 2020; 11():1439. PubMed ID: 32655577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
    Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case Report of Neonatal Acute Respiratory Failure Due to Severe Acute Respiratory Syndrome Coronavirus-2.
    Precit MR; Yee R; Anand V; Mongkolrattanothai K; Pandey U; Dien Bard J
    J Pediatric Infect Dis Soc; 2020 Jul; 9(3):390-392. PubMed ID: 32441743
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
    Michot JM; Albiges L; Chaput N; Saada V; Pommeret F; Griscelli F; Balleyguier C; Besse B; Marabelle A; Netzer F; Merad M; Robert C; Barlesi F; Gachot B; Stoclin A
    Ann Oncol; 2020 Jul; 31(7):961-964. PubMed ID: 32247642
    [No Abstract]   [Full Text] [Related]  

  • 14. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
    Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
    Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
    Assimakopoulos SF; Seintis F; Marangos M
    Med Hypotheses; 2020 Oct; 143():109926. PubMed ID: 32485316
    [No Abstract]   [Full Text] [Related]  

  • 17. Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study.
    Procopio G; Cancelliere A; Trecarichi EM; Mazzitelli M; Arrighi E; Perri G; Serapide F; Pelaia C; Lio E; Busceti MT; Pelle MC; Ricchio M; Scaglione V; Davoli C; Fusco P; La Gamba V; Torti C; Pelaia G
    Ther Adv Respir Dis; 2020; 14():1753466620963016. PubMed ID: 33070706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of anakinra in severe COVID-19: A case report.
    Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
    Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive Management and Interventions for Respiratory Failure Due to SARS-CoV-2.
    Baltaji S; Ledgerwood C; Finoli L; Lyons C; Cheema T
    Crit Care Nurs Q; 2020; 43(4):369-380. PubMed ID: 32833773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
    Caocci G; La Nasa G
    Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.